Thanks for raisin that and just read the article and it does a good job of covering the key points. Interesting he has some of his grammar at different points in time. He clearly knows about the RHB-106 return to RedHill that just happened, but apparently doesn't know that Aemcolo was already officially launched earlier in Q42019.
Something I find interesting too between RedHill and Protalix is that, RedHill has a product for IBS (Bekinda) and Crohn's (RHB-104), where Protalix in OPRX-106 also has a product to tackle both of these. Perhaps they could share the market if RedHill goes for less severe patients, and Protalix goes for more severe patients, particularly as inside OPRX-106 is the most expensive go-to product, anti-TNFalpha. I expect very good things from OPRX-106, and especially if given to patients longer than the Phase II trial of 8 weeks.
That they reached 67% Clinical Response and 28% Complete Remission, in 8 weeks is very well done. And with the added benefit of no real adverse events and the elimination of systemic exposure of the drug. Looking forward to the next 3-4 years. Hoping that's all I'll need :)
NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • NNVC • May 2, 2024 10:07 AM
ILUS Files Form 10-K and Provides Shareholder Update • ILUS • May 2, 2024 8:52 AM
Avant Technologies Names New CEO Following Acquisition of Healthcare Technology and Data Integration Firm • AVAI • May 2, 2024 8:00 AM
Bantec Engaged in a Letter of Intent to Acquire a Small New Jersey Based Manufacturing Company • BANT • May 1, 2024 10:00 AM
Cannabix Technologies to Deliver Breath Logix Alcohol Screening Device to Australia • BLO • Apr 30, 2024 8:53 AM
Hydromer, Inc. Reports Preliminary Unaudited Financial Results for First Quarter 2024 • HYDI • Apr 29, 2024 9:10 AM